Orthonika was awarded a £1.3 million grant (USD ~$1.7 million) from Innovate UK to complete pre-clinical development and testing of its synthetic total meniscus replacement in preparation for the clinic.
This is the fifth Innovate UK grant awarded to Orthonika, bringing total grant funding to £2 million. The company has also raised equity funding to further support its R&D efforts.
Orthonika’s total meniscus replacement is an orthopedic implant for the knee joint that is designed to replicate the structure and function of the native meniscus in a first-of-its-kind synthetic option for patients. The implant features an inherent attachment mechanism incorporated into the underlying structure, allowing optimal load transfer and distribution in the knee joint during mobility. Orthonika’s implant aims to restore the biomechanical function of the meniscus to help reduce pain, improve mobility and ultimately delay the onset of osteoarthritis. It is intended to fill the gap between minimally invasive meniscus repair and total knee replacement.
“There is currently no widely available treatment solution that allows patients to return to a pain free active lifestyle following meniscectomy,” said Maria Kristina Bartolo, PhD, Chief Technology Officer at Orthonika. “We are delighted that Innovate UK has recognised the potential for our novel total meniscus replacement to fulfil a significant unmet clinical need and further promote joint preservation.”
Dominique Kleyn, Co-Founder and Chief Operating Officer, said, “This highly competitive award brings additional resource for Orthonika to further expand the team, engage with development partners and manufacturers, and accelerate plans to take our total meniscus replacement product into first in human studies.”
Orthonika was awarded a £1.3 million grant (USD ~$1.7 million) from Innovate UK to complete pre-clinical development and testing of its synthetic total meniscus replacement in preparation for the clinic.
This is the fifth Innovate UK grant awarded to Orthonika, bringing total grant funding to £2 million. The company has also raised equity...
Orthonika was awarded a £1.3 million grant (USD ~$1.7 million) from Innovate UK to complete pre-clinical development and testing of its synthetic total meniscus replacement in preparation for the clinic.
This is the fifth Innovate UK grant awarded to Orthonika, bringing total grant funding to £2 million. The company has also raised equity funding to further support its R&D efforts.
Orthonika’s total meniscus replacement is an orthopedic implant for the knee joint that is designed to replicate the structure and function of the native meniscus in a first-of-its-kind synthetic option for patients. The implant features an inherent attachment mechanism incorporated into the underlying structure, allowing optimal load transfer and distribution in the knee joint during mobility. Orthonika’s implant aims to restore the biomechanical function of the meniscus to help reduce pain, improve mobility and ultimately delay the onset of osteoarthritis. It is intended to fill the gap between minimally invasive meniscus repair and total knee replacement.
“There is currently no widely available treatment solution that allows patients to return to a pain free active lifestyle following meniscectomy,” said Maria Kristina Bartolo, PhD, Chief Technology Officer at Orthonika. “We are delighted that Innovate UK has recognised the potential for our novel total meniscus replacement to fulfil a significant unmet clinical need and further promote joint preservation.”
Dominique Kleyn, Co-Founder and Chief Operating Officer, said, “This highly competitive award brings additional resource for Orthonika to further expand the team, engage with development partners and manufacturers, and accelerate plans to take our total meniscus replacement product into first in human studies.”
Copy to clipboard 
